期刊文献+

达比加群酯降解杂质的合成 被引量:1

Synthesis of the Degradation Impurities of Dabigatran Etexilate Mesylate
原文传递
导出
摘要 目的为了更好的控制甲磺酸达比加群酯的质量,合成达比加群酯的5个降解杂质。方法以N-[[2-[[(4-氰基苯基)氨基]甲基]-1甲基-1H-5-苯并咪唑]羰基]-N-2-吡啶基-β-氨基丙酸乙酯为原料,经过成脒反应、酰胺反应、水解反应制备了杂质A^E。结果所得产物经1H-NMR,LC-MS和13C-NMR初步确证了结构,收率≥65%。结论该合成路线反应条件温和,产品纯度高。 OBJECTIVE To perform the quality control of dabigatran etexilate mesylate, five degradation impurities recorded in quality specifications are prepared. METHODS Five degradation impurities A?E were synthesized from N-[[2-[[(4-cyanophenyl)amino]methyl]-1-methyL^-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-alanine ethyl ester, via amidine reaction, amidation reaction and hydrolytic reaction. RESULTS The strutures of five degradation impurities were established by 1H-NMR, LC-MS and ^13C-NMR, with yield ≥65%. CONCLUSION The reaction condition is mild, and the purity is high.
出处 《中国现代应用药学》 CAS CSCD 2015年第9期1090-1093,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 甲磺酸达比加群酯 降解杂质 合成 dabigatran etexilate mesylate degradation of impurity synthesis
  • 相关文献

参考文献8

二级参考文献42

  • 1孙平华,唐文生,张虎山,孙铁民.依巴斯汀的合成工艺改进[J].中国医药工业杂志,2004,35(6):326-327. 被引量:7
  • 2中国药典.二部[S].2010:凡例ⅩⅦ. 被引量:160
  • 3European Medicines Agency. CHMP assessment report for pradaxa [2008-02]. http://www.ema.europa.eu/docs/en_GB/ document library/EPAR - Summary_for_the_public/ human/000829/WC500041060.pdf. 被引量:1
  • 4Sanford M, Plosker GL. Dabigatran etexilate [J]. Drugs, 2008, 68 (12) : 1699-1709. 被引量:1
  • 5Spyropoulos AC. Brave new world: the current and future use of novel anticoagulants [J]. Thromb Res, 2008, 123 (Suppl 1) : S29-35. 被引量:1
  • 6Baetz BE, Spinier SA. Dabigatran Etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases [J]. Pharmacotherapy, 2008, 28(11): 1354-1373. 被引量:1
  • 7Hauel N, Ries U, Priepke H, et al. Preparation of amidino- phenylethylbenzimidazolylcarboxamides and related compounds as thrombin inhibitors: WO, 9837075 [P]. 1998-08-27. (CA 1998, 129: 216617). 被引量:1
  • 8林国强,马景毅,徐亮,等.一种合成非手性,非肽类的抗凝血酶抑制剂的方法:中国,1861596[P].2006-11-15.(CA2006,146:27828). 被引量:2
  • 9Hauel NH, Nat H, Priepke H, et aL Structure-based design of novel potent nonpeptide thrombin inhibitors [J]. J Med Chem, 2002, 45 (9): 1757-1766. 被引量:1
  • 10Jirman J, Richter J, Lustig P. Process for the preparation of dabigatran from 4-methylamino-3-nitrobenzoyl chloride, ethyl 3- (pyridin-2-ylamino) propanoate, [ (4-cyanophenyl) - amino] acetic acid, and hexyl chloroformate: WO, 2009111997 [P]. 2009-09-17. (CA2009, 151: 358757). 被引量:1

共引文献18

同被引文献12

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部